KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Short term Debt (2019 - 2025)

Vir Biotechnology's Short term Debt history spans 5 years, with the latest figure at $17.5 million for Q1 2025.

  • On a quarterly basis, Short term Debt changed N/A to $17.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $17.5 million, a N/A change, with the full-year FY2024 number at $16.1 million, changed N/A from a year prior.
  • Short term Debt hit $17.5 million in Q1 2025 for Vir Biotechnology, up from $16.1 million in the prior quarter.
  • Over the last five years, Short term Debt for VIR hit a ceiling of $68.5 million in Q3 2021 and a floor of $16.1 million in Q4 2024.
  • Historically, Short term Debt has averaged $30.5 million across 3 years, with a median of $24.4 million in 2021.
  • The widest YoY moves for Short term Debt: up 457.45% in 2021, down 128.04% in 2021.
  • Tracing VIR's Short term Debt over 3 years: stood at $68.5 million in 2021, then plummeted by 76.55% to $16.1 million in 2024, then increased by 8.97% to $17.5 million in 2025.
  • Business Quant data shows Short term Debt for VIR at $17.5 million in Q1 2025, $16.1 million in Q4 2024, and $68.5 million in Q3 2021.